Intas Pharmaceuticals Ltd on Wednesday announced that the company has received permission from the Drug Controller General of India (DCGI) to conduct clinical trials by using a newly-developed Covid-19-specific hyperimmune globulin. These are antibody-rich blood products made from blood donated by people who have recovered from the virus.
In a major breakthrough for Covid-19 treatment, the R&D team at Intas has developed hyperimmune globulin as treatment for patients suffering from moderate to severe Covid-19 infection.
Seen as an important therapeutic option to potentially help combat Covid-19 until a vaccine is made available, hyperimmune globulin has a potential for use as prophylaxis for all high-risk population in contact with Covid-19 patients.
Earlier, the US drug regulator US Food and Drug Administration (USFDA) had endorsed two investigational therapies derived from human blood which included convalescent plasma and hyperimmune globulin.
“There are some limited data to suggest that convalescent plasma and hyperimmune globulin